Cigna Group (CI) Financials

Cigna Group’s recent results show strong earnings growth and revenue expansion, but cash flow and leverage have become increasingly uneven. Comparing second-quarter results from 2023 through 2026, revenue rose from $48.6 billion to $71.6 billion, while net income attributable to common shareholders increased from $1.46 billion to $1.66 billion. Diluted earnings per share improved from $4.92 to $6.29 over the same period.

• Revenue has expanded steadily. Second-quarter revenue increased 6.5% year over year to $71.6 billion in 2026 and was approximately 48% above the comparable 2023 period. The increase has been driven primarily by growth in other non-interest income, which reached $61.5 billion in Q2 2026.
• Earnings per share continue to benefit from shareholder returns. Diluted EPS rose to $6.29 in Q2 2026 from $5.71 in Q2 2025, $5.45 in Q2 2024 and $4.92 in Q2 2023. The weighted-average diluted share count also declined to 264.2 million from 296.0 million in Q2 2023.
• Net income has remained resilient despite quarterly volatility. Q2 2026 net income attributable to common shareholders was $1.66 billion, up from $1.53 billion in Q2 2025 and $1.55 billion in Q2 2024.
• The balance sheet has recovered from its 2025 low point. Total assets increased to $157.1 billion in Q2 2026 from $151.7 billion a year earlier, while total equity rose to $42.9 billion from $40.4 billion.
• Cash levels improved year over year. Cash and equivalents increased to $6.3 billion at the end of Q2 2026 from $4.3 billion at the end of Q2 2025, although cash remains below the $9.6 billion reported in Q2 2023.
• Premium revenue has been relatively stable but is no longer the primary growth engine. Premiums earned were $9.9 billion in Q2 2026, compared with $9.2 billion in Q2 2025 and $11.5 billion in Q2 2024. The sharp increase in total revenue has instead come from other non-interest income.
• Investment gains are helping results but remain unpredictable. Net realized and unrealized investment gains ranged from a $923 million loss in Q3 2024 to a $471 million gain in Q1 2026 and a $209 million gain in Q2 2026. This volatility can materially affect quarterly earnings.
• Operating cash flow has weakened significantly. Cigna reported negative operating cash flow of $421 million in Q2 2026, following negative operating cash flow of $1.9 billion in Q2 2025. This contrasts with positive operating cash flow of $2.5 billion in Q2 2023 and $265 million in Q2 2024.
• Working-capital movements are consuming cash. Changes in operating assets and liabilities reduced Q2 2026 operating cash flow by $3.0 billion. The comparable reduction was $5.0 billion in Q2 2025, highlighting the extent to which cash generation has been affected by balance-sheet timing and operating capital requirements.
• Debt increased sharply in the latest quarter. Short- and long-term debt totaled approximately $75.2 billion at June 30, 2026, up from $40.7 billion a year earlier and $41.2 billion in Q2 2024. Total liabilities reached $114.2 billion, leaving Cigna with a higher leverage burden relative to its $42.9 billion of equity.

Cigna’s income statement remains the strongest part of the analysis: revenue is growing, earnings are positive, and per-share results have benefited from a lower share count. However, investors should closely monitor whether operating cash flow improves and whether the recent increase in debt is temporary or becomes a persistent feature of the balance sheet. The company’s earnings quality also warrants attention because other non-interest income and investment gains account for a substantial portion of reported revenue and can be volatile.